Placebo matching Obicetrapib 10 mg tablets, Obicetrapib, Placebo matching Obicetrapib 10 mg + ezetimibe 10 mg fixed dose combination (FDC) tablets, Obicetrapib 10 mg + ezetimibe 10 mg fixed dose combination (FDC)
OBEZ-303
Phase 3 small_molecule active
Quick answer
Placebo matching Obicetrapib 10 mg tablets, Obicetrapib, Placebo matching Obicetrapib 10 mg + ezetimibe 10 mg fixed dose combination (FDC) tablets, Obicetrapib 10 mg + ezetimibe 10 mg fixed dose combination (FDC) for Adults with Type 2 Diabetes and/or Metabolic Syndrome on guideline recommended lipid lowering therapy and elevated low-density lipoprotein cholesterol (LDL-C) is a Phase 3 program (small_molecule) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pharma Mar S.A.
- Indication
- Adults with Type 2 Diabetes and/or Metabolic Syndrome on guideline recommended lipid lowering therapy and elevated low-density lipoprotein cholesterol (LDL-C)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active